Elanco Animal Health Incorporated (ELAN) Presents at Leerink Global Healthcare Conference 2026 Transcript

Core Insights - Elanco is experiencing significant momentum, ending Q4 with strong performance that exceeded guidance across revenue, earnings, and cash flow metrics [2] - The company reported $892 million in revenue from its innovation basket, surpassing previous guidance, and has raised expectations for this segment to $1.150 billion by 2026 [2] Financial Performance - Elanco's Q4 results showed a strong finish, with revenue and earnings beating expectations [2] - Cash flow performance was notably strong, allowing the company to reduce leverage more than anticipated [2] Future Outlook - The company provided guidance for 2026, projecting mid-single-digit top line growth and high single-digit EBITDA growth, consistent with previous forecasts made during the Investor Day in December [3]